JAC Advance Access published online on July 28, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh396
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
* To whom correspondence should be addressed. E-mail: Adrianna.Weinberg{at}uchsc.edu.
The incidence of cytomegalovirus (CMV) disease, once the most common and highly feared viral complication of AIDS, has dramatically decreased with the advent of highly active antiretroviral therapy (HAART). HAART-associated changes in the epidemiology of CMV disease resulted from the increase in CMV-specific immune responses coupled with the decrease in CMV reactivation. However, CMV disease continues to afflict HIV-infected patients on HAART when CD4+ cell counts fail to rise above 100 cells/mm3 and when reconstitution of normal CMV-specific immune responses does not occur. The latter scenario may lead to recurrent or de novo CMV end-organ disease, or to the recently described CMV immune recovery vitritis. HAART-associated immune reconstitution offers unique opportunities to investigate the virological and immunological correlates of protection against CMV disease. Although the full extent of CMV-specific immune reconstitution has not been defined thus far, CMV-specific interferon-
Leading article
Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity
2 Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA; Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA
![]()
Abstract
production has been shown to be significantly associated with protection against CMV reactivation and recurrent disease.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Kahaleh The microvascular endothelium in scleroderma Rheumatology, October 1, 2008; 47(suppl_5): v14 - v15. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Ryckman, B. L. Rainish, M. C. Chase, J. A. Borton, J. A. Nelson, M. A. Jarvis, and D. C. Johnson Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells J. Virol., January 1, 2008; 82(1): 60 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Miller, J. R. Berger, Y. Mootoor, S. A. Avdiushko, H. Zhu, and R. J. Kryscio High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J. Clin. Microbiol., July 1, 2006; 44(7): 2409 - 2415. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Stone, P. Price, and M. A. French Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease J. Antimicrob. Chemother., April 1, 2006; 57(4): 585 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Tchesnokov, C. Gilbert, G. Boivin, and M. Gotte Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet J. Virol., February 1, 2006; 80(3): 1440 - 1450. [Abstract] [Full Text] [PDF] |
||||



